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Raf kinase inhibitory protein (RKIP) negatively regulates
the MAP kinase (MAPK), G protein-coupled receptor
kinase-2, and NF-jB signalling cascades. RKIP has been
implicated as a metastasis suppressor for prostate cancer,
but the mechanism is not known. Here, we show that
RKIP inhibits invasion by metastatic breast cancer cells
and represses breast tumour cell intravasation and bone
metastasis in an orthotopic murine model. The mechan-
ism involves inhibition of MAPK, leading to decreased
transcription of LIN28 by Myc. Suppression of LIN28
enables enhanced let-7 processing in breast cancer cells.
Elevated let-7 expression inhibits HMGA2, a chromatin
remodelling protein that activates pro-invasive and pro-
metastatic genes, including Snail. LIN28 depletion and let-
7 expression suppress bone metastasis, and LIN28 restores
bone metastasis in mice bearing RKIP-expressing breast
tumour cells. These results indicate that RKIP suppresses
invasion and metastasis in part through a signalling
cascade involving MAPK, Myc, LIN28, let-7, and down-
stream let-7 targets. RKIP regulation of two pluripotent
stem cell genes, Myc and LIN28, highlights the importance
of RKIP as a key metastasis suppressor and potential
therapeutic agent.
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Introduction
Tumour metastasis suppressors are natural regulators of the
metastasic process (Massague, 2007). Some of these suppres-
sors prevent progression of tumour cells to metastasis; other
suppressors not only block progression, but are also able to
reverse the metastatic phenotype. One powerful strategy for
both prevention and treatment of aggressive tumours is to
identify tumour metastasis suppressors that inhibit the viru-
lent invasive and colonizing properties of metastatic cells and
to mimic their mechanism of action.
Raf kinase inhibitory protein (RKIP; also PEBP1), a mem-
ber of the evolutionarily conserved phosphatidylethanola-
mine-binding protein family, has been implicated as a
suppressor of metastatic progression in an orthotopic murine
model using androgen-independent prostate tumour cells
(Fu et al, 2003). Although primary prostate tumour growth
was unaffected, RKIP inhibited both vascular invasion and
lung metastases. RKIP is depleted or deficient in a number
of tumours, including prostate, breast, melanoma, hepato-
cellular carcinoma, and colorectal (Fu et al, 2003, 2006;
Schuierer et al, 2004; Hagan et al, 2005; Akaishi et al, 2006;
Al-Mulla et al, 2006). Taken together, these results suggest
that RKIP may function as a general metastasis suppressor.
Raf kinase inhibitory protein modulates at least three key
regulatory pathways in mammalian cells. RKIP inhibits MAP
kinase (MAPK) signalling in part by binding to Raf-1, prevent-
ing Raf-1 phosphorylation at activating sites (Yeung et al, 1999;
Trakul et al, 2005). RKIP phosphorylation at S153 by protein
kinase C dissociates RKIP from Raf, enabling MEK and MAPK
activation. Phosphorylated RKIP inhibits G protein-coupled
receptor kinase-2 (GRK-2)-mediated downregulation of G pro-
tein-coupled receptors (GPCRs), thereby mediating cross talk
between MAPK and GPCR signalling pathways (Lorenz et al,
2003). RKIP also suppresses NF-kB activation (Yeung et al,
2001), potentiating the efficacy of chemotherapeutic agents
(Chatterjee et al, 2004). Finally, RKIP ensures chromosomal
integrity by preventing MAPK inhibition of Aurora B kinase
and the spindle checkpoint (Eves et al, 2006). Although
genomic instability resulting from RKIP loss could contribute
to metastatic progression, this mechanism is unlikely to give
rise to a common phenotype in multiple tumour types.
Metastasis is a complex process involving a number of
steps, including cellular epithelial–mesenchymal transition
(EMT), invasion, intravasation into blood or lymph vessels,
extravasation from vessels, and metastatic colonization, pro-
liferation, and survival (Massague, 2007). EMT is regulated
by the transcription factors Snail, Twist, and Slug, which are
themselves regulated by the high mobility group A (HMGA1
and 2) family of non-histone chromatin remodelling proteins
(Thuault et al, 2006). Recently, HMGA2 has been shown to be
inhibited by the microRNA let-7 (Lee and Dutta, 2007;
Mayr et al, 2007).
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MicroRNAs are non-coding RNAs of B22 nucleotides
that regulate key processes in growth and development
and have been implicated as tumour oncogenes or suppres-
sors in cancer (Wu et al, 2007). Let-7/miR-98 is an evolutio-
narily conserved microRNA family that has been implicated
as a tumour suppressor of colon and lung cancer, and let-7
loss is associated with breast tumours as well as other
less differentiated human cancer cells (Shell et al, 2007;
Zhang et al, 2007). However, the signalling cascades that
regulate let-7 expression in mammalian cells have not been
elucidated.
To examine the mechanism by which RKIP suppresses
metastasis, we focused on early and late events in bone
metastasis using a breast tumour model. Here, we show
that RKIP represses invasion, intravasation and bone meta-
stasis of breast tumour cells in part through a signalling
cascade involving inhibition of MAPK, Myc, and LIN28,
leading to induction of the microRNA let-7 and downregula-
tion of its targets.
Results
Raf kinase inhibitory protein is expressed in MCF10A
mammary gland and MCF-7 cells but is barely detectable in
the highly invasive MDA-MB-231 adenocarcinoma cells
(Figure 1A, Supplementary Figure 1a and d). To determine
the effect of RKIP on invasion, we transduced MDA-MB-231
cells with lentivirus-expressing wild-type (wt) RKIP or an
S153E mutant. Phosphorylation at S153 causes RKIP disso-
ciation from Raf-1, and mutating this site results in a more
potent MAPK inhibitor (Corbit et al, 2003). The S153E mutant
does not function as a phosphomimetic but instead promotes
selective inhibition of Raf by preventing phosphorylation and
GRK-2 inhibition. As observed previously for prostate cells
(Fu et al, 2003), RKIP did not affect breast tumour cell growth
in culture or in mice (Supplementary Figure 2a and b).
However, stable expression of wt RKIP in MDA-MB-231 cells
inhibited invasion without changing E-cadherin or vimentin
levels (Figure 1B; Supplementary Figure 1b and c). The S153E
mutant induces similar effects at lower expression levels in
MDA-MB-231 cells, consistent with Raf-1 as an RKIP target.
These results show that RKIP suppresses invasion, an early
step in metastasis.
MDA-MB-231 cells are a heterogeneous population show-
ing clonal variability in metastatic behaviour (Minn et al,
2005b). To avoid potential confounding effects in studying a
mixed population, we introduced wt and S153E RKIP into
highly metastatic lung-tropic (4175) and bone-tropic (1833)
breast tumour cells derived from MDA-MB-231 by in vivo
selection (Kang et al, 2003; Minn et al, 2005a) (Figure 1C and
D). As in the parental population, RKIP inhibited in vitro
invasion of both 4175 and 1833 cells, and S153E more
potently inhibited invasion compared with wt RKIP
(Figure 1E and F). As RKIP inhibited invasion more robustly
in bone- than in lung-tropic cells by in vitro assays, 1833 cells
were used for in vivo experiments and to delineate the
mechanism of RKIP inhibition. To test RKIP regulation of
invasion in vivo, we determined its effect on tumour cell
intravasation from a primary site in a murine orthotopic
model. The 1833 cells expressing control vector, wt RKIP,
or S153E RKIP were injected into the mammary fat pad. At 3
weeks, cells isolated from the blood were lysed and analysed
for human (tumour) and mouse (control) GAPDH transcripts.
qRT–PCR quantitation showed that both wt RKIP and S153E
RKIP inhibited tumour cell intravasation (Figure 1G).
Invasion and intravasation are necessary early events in
the metastatic cascade. To determine if RKIP can also
suppress late metastatic events, such as colonization and/or
growth at a distant site, we injected luciferase-labelled 1833
cells co-expressing a control vector, wt RKIP, or S153E RKIP
directly into the left cardiac ventricle of mice to bypass the
intravasation step. Bioluminescence imaging approximately 3
weeks post-injection showed colonization and growth of
bone metastatic cells in the skull (a primary osseous site in
adult mice) for the control cohort. Analysis of the dissected
brain showed no tumour cells, illustrating selective metasta-
sis to the skull. In contrast, RKIP-expressing cells showed a
marked decrease in bone metastasis (Figure 1H and I),
confirming that RKIP is a suppressor of breast cancer
metastasis.
Epithelial–mesenchymal transition is thought to be an
important process in tumour invasion and intravasation.
HMGA2 is a chromatin remodelling factor that induces
transcription factors implicated in EMT and invasion such
as Snail (Thuault et al, 2006). Recently, the let-7/miR-98
family of microRNAs was shown to negatively regulate
HMGA2 (Lee and Dutta, 2007; Mayr et al, 2007). As let-7
also inhibits MAPK signalling through suppression of Ras
(Johnson et al, 2005), the actions of RKIP and let-7 are
similar, and we reasoned that they may suppress invasion
through common signalling pathways.
To investigate this possibility, we determined whether let-7
and its targets are influenced by RKIP and mediate RKIP
inhibition of invasion. MCF10A cells express higher levels of
let-7a than MDA-MB-231 cells, and shRNA depletion of RKIP
in MCF10A cells almost completely suppresses let-7a and
let-7g expression (Figure 2B, Supplementary Figure 3a).
Conversely, 1833 cells transfected with wt RKIP or S153E
RKIP exhibit an increase in let-7a and let-7g expression
(Figure 2A). As we did not assay the other human let-7 family
members with similar binding sites, this induction is prob-
ably an underestimate of total let-7 expression. To directly
examine the consequences of altering let-7 expression, we
transfected 1833 cells with precursor (pre-miR) let-7a. Pre-
miR let-7a increased the level of Dicer-processed mature
let-7a approximately three-fold, decreased HMGA2 and
Snail (Figure 2C, Supplementary Figure 3c and d), and
decreased invasion, but proliferation was unaffected
(Figure 2G; Supplementary Figure 2c). By contrast, electro-
porating S153E RKIP or wt RKIP-expressing cells with let-7a
anti-miR, an inhibitor of let-7, decreased the level of let-7a
expression and increased HMGA2 and Snail (Figure 2D,
Supplementary Figure 3e–h). Anti-miR let-7a also promoted
invasion (Figure 2G and H) under conditions where
proliferation of RKIP-expressing cells was unchanged
(Supplementary Figure 2d). Similar to let-7, wt and S153E
RKIP inhibited HMGA2 protein and Snail mRNA expression
in both MDA-MB-231 and 1833 cells (Figure 2E and F,
Supplementary Figure 3b). Furthermore, an HMGA2 cDNA
lacking let-7 interaction sites (Lee and Dutta, 2007) restored
both Snail expression and invasion in S153E RKIP-expressing
1833 cells (Figure 2F and I), whereas an shRNA for HMGA2
decreased invasion in 1833 cells (Figure 2J). No changes in
proliferation rate were observed under the same conditions as
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the invasion assays (Supplementary Figure 2e and f). In total,
these results argue that RKIP inhibits invasion in part through
induction of let-7 and inhibition of HMGA2 and Snail.
As RKIP is also a metastasis suppressor, we determined
whether let-7 similarly represses bone metastasis. To address
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Figure 1 RKIP regulates breast cancer invasion and metastasis. (A) RKIP is expressed in MCF10A mammary gland and depleted in metastatic
MDA-MB-231 cells. MDA-MB-231 cells were stably transduced with wt or S153E RKIP and the lysates immunoblotted with anti-RKIP or anti-
tubulin antibody. (B) Wt and S153E RKIP inhibit invasion of MDA-MB-231 cells. Cells were assayed for invasion as described in Materials and
methods. Results represent the mean±s.e. for four independent samples (Po0.001 for wt and P¼ 0.002 for S153E RKIP relative to Control).
(C, D) Expression of wt and S153E RKIP in lung-tropic (4175) or bone-tropic (1833) breast cancer cells. Cells were stably transduced with wt or
S153E RKIP and the lysates were immunoblotted with anti-RKIP or anti-tubulin antibody. All lanes in (C) come from the same gel, but one lane
after sample 2 was omitted leading to a composite figure. (E, F) Wt and S153E RKIP inhibit invasion of lung-tropic (4175) or bone-tropic (1833)
cells. The 1833 cells stably expressing control vector, wt RKIP, or S153E RKIP were assayed for invasion as described in Materials and methods.
Results represent the mean±s.e. for four independent samples (4175) or mean±s.d. for three samples (1833) (Po0.05 for wt RKIP and Po0.05
for S153E RKIP relative to control 4175 cells; P¼ 0.02 for wt RKIP and Po0.001 for S153E RKIP relative to control 1833 cells). (G) Wt and S153E
RKIP inhibit intravasation of bone-tropic tumour cells (1833). The 1833 cells stably expressing control vector (six mice), wt RKIP (five mice), or
S153E RKIP (five mice) were injected into the mammary fat pad of mice. After 3 weeks, cells isolated from the blood were analysed for GAPDH
transcripts derived from human (tumour) or mouse (control). Results represent the mean±s.d. for the animals (Po0.002 for wt RKIP and
Po0.001 for S153E RKIP relative to control). (H, I) Wt and S153E RKIP inhibit bone metastases. The 1833 cells expressing luciferase and
control vector (six mice), wt RKIP (seven mice), or S153E RKIP (seven mice) were injected into the left ventricle of the mice, and the mice were
imaged for luciferase activity after 3 weeks. Representative images show that RKIP wt and S153E greatly reduced bone metastases in skull
(H, upper right panel; lower right panel). The 1833 cells stably expressing luciferase have an identical luciferase reporter activity before
injection into mice (H, lower left panel). Comparable regions of the mouse skulls were optically imaged and quantified. Results (I) represent the
mean±s.d. for the animals (Po0.01 for wt RKIP and Po0.01 for S153E RKIP relative to Control).
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Figure 2 RKIP regulates let-7, HMGA2, and Snail. (A) Wt and S153E RKIP increase let-7a and let-7g expression. The 1833 cells expressing
control, wt, or S153E were assayed for let-7a or let-7g by qRT–PCR. Results represent the mean±s.d. for three samples (P¼ 0.03 for wt RKIP
and Po0.01 for S153E RKIP relative to control). (B) Depletion of RKIP in MCF10A cells suppresses let-7a and let-7g expression. MCF10A cells
expressing control vector or shRNA for human RKIP were assayed for let-7a or let-7g by qRT–PCR. Results represent the mean±s.d. for three
samples (Po0.0001 for MCF10A/shRKIP relative to MCF10A cells). Cell lysates were immunoblotted with anti-RKIP or anti-tubulin antibodies.
(C) Pre-miR let-7a decreases Snail mRNA levels. Snail mRNA isolated from 1833 cells transfected with pre-miR let-7a was quantitated by qRT–
PCR. Results represent the mean±s.d. for three samples (Po0.02 for let-7a relative to Control). (D) Anti-miR let-7a increases Snail mRNA
levels. Snail mRNA isolated from 1833 cells stably expressing S153E RKIP and transfected with anti-miR let-7a was quantitated by qRT–PCR.
Results represent the mean±s.d. for three samples (P¼ 0.03 for anti-miR let-7a relative to Control). (E) RKIP inhibits HMGA2 expression. The
1833 cells expressing vector, wt, or S153E RKIP were lysed and immunoblotted with anti-HMGA2 or anti-tubulin antibody. (F) Snail expression
inhibited by RKIP and rescued by let-7-insensitive HMGA2. Snail mRNA was isolated from 1833 cells expressing control vector, wt RKIP, S153E
RKIP, or S153E RKIP and HMGA2 lacking the 30-untranslated region that binds let-7 (ORF). Snail mRNA was quantitated by qRT–PCR. Results
represent the mean±s.e. for three independent samples (Po0.001 for wt RKIP and for S153E RKIP relative to control). (G, H) Let-7 regulates
invasion. The 1833 cells were transfected with control or pre-miR let-7a, and 1833 cells expressing S153E or wt RKIP were transfected with
control or anti-miR let-7a. Cells were assayed for invasion as described in Materials and methods. Results represent the mean±s.e. for four
independent samples. (P¼ 0.004 for pre-miR let-7 relative to Control, P¼ 0.008 for anti-miR let-7 relative to Control in S153E RKIP cells, and
P¼ 0.025 for anti-miR let-7 relative to Control in wt RKIP cells). (I, J) HMGA2 regulates invasion. The 1833 cells were transfected with either
HMGA2 ORF or shRNA for HMGA2 (shHMGA2). Cells were lysed at 18 and 48 h after transfection of HMGA2 ORF or 48 h after transfection of
shHMGA2 and immunoblotted with anti-HMGA2 or anti-tubulin antibody. Cells were assayed for invasion as described in Materials and
methods. Results represent the mean±s.e. for three independent samples (I: P¼ 0.02 for HMGA2 relative to Control; J: Po0.04 for shHMGA2
relative to Control). Results are representative of at least three independent experiments.
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inducible expression vectors for let-7g as described pre-
viously (Kumar et al, 2008). Doxycycline did not affect cell
growth or invasion in control 1833 cells (data not shown). By
contrast, as observed with pre-miR let-7, doxycycline-induced
let-7g inhibited cell invasion (Supplementary Figure 4a).
Under these conditions (up to 48 h of let-7 induction), no
change in cell proliferation was observed (Supplementary
Figure 4b), although longer incubation showed some inhibi-
tion of cell proliferation. When luciferase-labelled 1833 cells
expressing inducible let-7g were injected into the left cardiac
ventricle of mice that were subsequently treated with dox-
ycycline, let-7 expression caused a dramatic decrease in bone
metastasis (Figure 3A and B). As the in vivo studies take at
least 3 weeks, it is possible that the let-7-mediated inhibition
is a secondary effect of decreased cell proliferation or in-
creased cell death. In either case, the net effect of let-7
expression, similar to RKIP, is to suppress breast cancer
metastasis.
How does RKIP regulate let-7? Let-7 expression can be
controlled at multiple levels, including synthesis of the primary
transcript, Drosha processing to the precursor, and Dicer
processing to the mature form (Wu et al, 2007). Analysis of
one of the three primary let-7a transcripts and the let-7g
primary transcript by qRT–PCR showed no increase in response
to wt RKIP or S153E RKIP (Figure 3C), indicating that regula-
tion occurs subsequent to primary transcription. Although it is
possible that let-7 transcribed from other loci might be subject
to transcriptional regulation by RKIP, these data indicate that
regulation can occur at the level of Drosha processing to the
precursor or Dicer processing to mature let-7.
Recently, LIN28, a regulator of developmental timing in
Caenorhabditis elegans that is downregulated by let-7 (Moss
et al, 1997; Morita and Han, 2006), was identified as an
inhibitor of let-7 primary transcript (pri-miRNA) processing
in vitro and in mammalian cells (Newman et al, 2008;
Viswanathan et al, 2008). To determine whether LIN28 can
regulate let-7 in breast cancer cells, we overexpressed LIN28
in 1833 cells transfected with vector, wt RKIP, or S153E RKIP.
LIN28 had little effect in the parental cells, possibly because
the LIN28 level in these cells is sufficiently high such that
maximal suppression of let-7 to a basal level has already
occurred (Figure 3D). By contrast, following induction of
let-7a and let-7g expression by RKIP, LIN28 suppressed let-7
back to the basal level (Figure 3D). These data suggest that
another regulatory mechanism is responsible for the basal or
background let-7 expression levels. Depletion of LIN28 was
shown to enhance let-7 expression (Newman et al, 2008;
Viswanathan et al, 2008), and LIN28 loss also upregulates let-
7 in 1833 cells (Supplementary Figure 4c). To assess whether
LIN28 exerts an effect downstream of RKIP to regulate
induction of let-7 expression, LIN28 transcripts were analysed
by qRT–PCR and immunoblotting. Both wt and S153E RKIP
decreased LIN28 mRNA and protein relative to control levels
in 1833 cells (Figure 3E). Taken together, these results
indicate that RKIP upregulates Drosha or Dicer processing
of let-7 via inhibition of LIN28.
If RKIP suppresses invasion and metastasis through a
cascade involving inhibition of LIN28, then depletion of
LIN28 should mimic RKIP action. To test this hypothesis,
we transduced lentivirus expressing shRNA for LIN28 into
luciferase-labelled 1833 cells. Loss of LIN28 protein was
confirmed by immunoblotting (Figure 3F). Depletion of
LIN28 caused a decrease in cell invasion (Figure 3G) but
had no effect on cell proliferation (Supplementary Figure 4d).
By contrast, transfection of LIN28 into wt RKIP-expressing
cells reversed the RKIP-mediated repression and rescued
invasion without altering cell growth (Supplementary
Figure 4f and g). Finally, injection of the LIN28-depleted
1833 cells into the cardiac ventricle of mice almost comple-
tely suppressed bone metastasis (Figure 3H). These data
show that LIN28 is required for breast cancer metastasis.
Myc represses the let-7 promoter directly in some cells
(Chang et al, 2008), and immunoblotting shows a decrease in
Myc protein in RKIP-expressing 1833 cells (Figure 4A). To
determine whether Myc can regulate let-7 expression by an
alternative mechanism involving LIN28, cells were assayed
by immunoblotting and qRT–PCR. Myc depletion by siRNA in
1833 cells decreases LIN28 protein and transcript levels, and
overexpression of Myc in 1833 S153E RKIP cells rescues the
loss of LIN28 protein and transcripts (Figure 4B and C). In
addition, Myc depletion enhances mature let-7 expression in
1833 cells, and Myc overexpression decreases let-7 transcripts
in 1833 S153E RKIP cells (Figure 4D). Thus, our data suggest
that Myc suppresses let-7 processing in 1833 cells by increas-
ing LIN28 transcripts.
Examination of the LIN28 promoter shows at least
one potential Myc-binding site. To determine whether Myc
directly regulates LIN28 transcription by binding to its pro-
moter, we performed quantitative chromatin immunopreci-
pitation (ChIP) assays. Lysates from 1833 cells were
immunoprecipitated with anti-Myc antibody, and the relative
association of Myc with the following gene promoters was
assessed: LIN28, Wnt5A (a positive control), and b-globin
(a negative control) (Figure 4E). As a positive control for the
assay, antibody to Jun was used to immunoprecipitate the
cyclin D1 promoter. ChIP analysis of cells expressing wt RKIP
or S153E RKIP showed that RKIP decreased Myc occupancy
of the LIN28 promoter relative to control cells, consistent
with the decreased Myc expression (Figure 4F).
If Myc induces LIN28, then Myc depletion should mimic
LIN28 depletion by suppressing invasion. As predicted, 1833
cells transfected with siRNA for Myc exhibited decreased
invasion relative to control cells (Figure 4G). Conversely,
Myc overexpression promoted invasion (Figure 4G). Under
the same conditions as the invasion assay, neither Myc
depletion nor Myc overexpression affected cell proliferation
(Supplementary Figure 5a). However, as Myc is required for
cell growth at longer incubation times, it was not possible to
assess the function of Myc in regulating metastasis in the
absence of major proliferative effects. These results show that
Myc binds to the LIN28 promoter to induce its transcription,
and RKIP reduces LIN28 expression through suppression of
Myc (see scheme in Figure 5).
As RKIP is an inhibitor of the Raf/MEK/MAPK signalling
cascade, we determined whether MAPK regulates Myc,
LIN28, and let-7 in breast epithelial cells. As observed pre-
viously for other cell types (Yeung et al, 1999; Trakul et al,
2005), RKIP depletion from MCF10A cells by shRNA upregu-
lates EGF-induced ERK activation, and RKIP expression in
1833 cells downregulates ERK activation (Supplementary
Figure 5b and c). Expression of constitutively active MEK
(MEK1-EE) enhances Myc and LIN28 expression; conversely,
stable depletion of MEK by shRNA or MEK inhibition by the
inhibitor U0126 decreases Myc and LIN28 expression
MAP kinase signalling and metastasis
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Figure 3 RKIP induces let-7 through the inhibition of LIN28. (A) Let-7g is induced by doxycycline. The 1833 cells expressing inducible let-7g were
treated with 2mg/ml doxycycline for the indicated times. Results represent the mean±s.d. for three samples (P¼ 0.006 for 24 h and P¼ 0.004 for
48 h treatment relative to Control). (B) Let-7g inhibits bone metastases. The 1833 cells expressing luciferase and either control vector (7 mice) or
tet-inducible let-7g (7 mice) were grown in the presence of 2mg/ml doxycycline for 24 h. Cells were injected into the left ventricle of mice, and 2
days later, mice were administered with drinking water containing 4% sucrose only or 2 mg/ml doxycycyline and 4% sucrose. Mice were imaged
for luciferase activity after 3 weeks. Representative images show let-7g greatly reduced bone metastases in skull. Results represent the mean±s.d.
for the animals (P¼ 0.001 for let-7g relative to Control). (C) RKIP does not alter primary let-7 expression. The 1833 cells expressing control vector,
wt RKIP, or S153E RKIP were lysed. Primary let-7a and let-7g transcripts were analysed by qRT–PCR. Results represent the mean±s.d. for three
samples. (D) LIN28 inhibits let-7 expression. The 1833 cells expressing control, wt RKIP, or S153E RKIP were stably transfected with LIN28
expression vector. Let-7a and g transcripts were analysed by qRT–PCR. Left: results represent the mean±s.d. for three samples (P¼ 0.01 and
Po0.001 for LIN28 in wt RKIP cells and S153E RKIP cells, respectively, relative to Control); Right: 1833 cells expressing control vector, wt RKIP, or
S153E RKIP were lysed and immunoblotted with anti-LIN28 or anti-tubulin antibodies. Results are representative of at least three independent
experiments. (E) RKIP decreased LIN28 mRNA in 1833 cells. The 1833 cells expressing control vector, wt RKIP, or S153E RKIP were lysed. LIN28
transcripts were analysed by qRT–PCR. Left: results represent the mean±s.d. for three samples (P¼ 0.003 for wt RKIP and P¼ 0.002 for S153E
RKIP relative to Control); right: 1833 cells expressing control vector, wt RKIP, or S153E RKIP were lysed and immunoblotted with anti-LIN28 or
anti-tubulin antibodies. Results are representative of at least three independent experiments. (F) shLIN28 downregulates LIN28 expression. The
1833 cells expressing control vector or shLIN28 were lysed and immunoblotted with anti-LIN28 or anti-tubulin antibodies. Results are
representative of at least three independent experiments. (G) LIN28 depletion inhibits invasion of 1833 cells. The 1833 cells expressing control
vector or shLIN28 were assayed for invasion as described in Materials and methods. Results represent the mean±s.d. for three independent
samples (P¼ 0.003 for shLIN28 relative to Control). (H) ShLIN28 inhibits bone metastasis. The 1833 cells expressing luciferase and vector control
(seven mice) or shRNA for LIN28 (eight mice) were injected into the left ventricle of mice. Mice were imaged for luciferase activity after 3 weeks.
Results represent the mean±s.d. for the animals (P¼ 0.002 for shLIN28 relative to Control).
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Control RKIP S153E 
Figure 4 Myc regulates LIN28 transcription. (A) RKIP downregulates Myc expression. Blot: 1833 cells expressing control vector, wt RKIP, or S153E
RKIP were lysed and immunoblotted with anti-Myc or anti-tubulin antibodies. Results are representative of at least three independent experiments.
Graph: results represent the mean±s.d. for three independent samples (P¼ 0.03 for wt RKIP and P¼ 0.003 for S153E RKIP relative to Control). (B)
Myc regulates LIN28 expression. The 1833 cells transfected with scrambled control or siRNA for Myc (left) or 1833 S153E RKIP cells transfected with
a control or a Myc expression vector (right) were lysed and immunoblotted with anti-Myc, anti-LIN28, or anti-tubulin antibodies. Results are
representative of at least three independent experiments. (C) Left: Myc regulates LIN28 transcript levels. The 1833 cells were transfected with a
control or siRNA for Myc. LIN28 and Myc transcripts were analysed by qRT–PCR 48 h after transfection. Right: 1833 cells expressing S153E RKIP
were transfected with a control or Myc expression vector. LIN28 transcripts were analysed by qRT–PCR 48h after transfection. Results represent the
mean±s.d. for three samples (Po0.0001 for siMyc and Po0.0001 for Myc relative to Control). (D) Myc regulates let-7 expression. The 1833 cells
were transfected with a control or siRNA for Myc. Let-7a and g transcripts were analysed by qRT–PCR 48 h after transfection. The 1833 cells
expressing S153E RKIP were transfected with a control or Myc expression vector. Let-7a and g transcripts were analysed by qRT–PCR 48 h after
transfection. Results represent the mean±s.d. for three samples (Po0.01 for siMyc and Po0.01 for Myc relative to Control). (E) Myc regulates LIN28
transcription by binding to its promoter. Schematic representation of LIN28 promoter with the putative Myc-binding site. Chromatin immunopre-
cipitations (ChIPs) were carried out with anti-Myc antibody and anti-Jun antibody (a positive control for ChIP assay). ChIP was analysed by qRT–
PCR, with primers in the LIN28, WNT5A (a positive control), CyclinD1 (a positive control for ChIP assay), and b-globin (a negative control; NC)
promoters. Results represent the mean±s.d. for three samples (Po0.004 for LIN28 relative to IgG). (F) RKIP regulates Myc binding to the LIN28
promoter. Chromatin immunoprecipitation (ChIP) were carried out with anti-Myc antibody on the LIN28 promoter. The 1833 cells expressing control
vector (C), wt RKIP, or S153E RKIP were treated with 2% serum or 2% serum with U0126 (10mM) for 2 h after 48h serum starvation. Results
represent the mean±s.d. for three samples (P¼ 0.01 and 0.001 for wt RKIP S153E RKIP, respectively, relative to untreated Control). (G) Myc
expression regulates invasion of 1833 cells. Top: 1833 cells transfected with scrambled control or siRNA for Myc were assayed for invasion as
described in Materials and methods. Results represent the mean±s.d. for three independent samples (P¼ 0.004 for siMyc relative to Control).
Bottom: 1833 S153E RKIP cells transfected with vector control or an expression vector for Myc were assayed for invasion as described in Materials
and methods. Results represent the mean±s.d. for three independent samples (P¼ 0.01 for Myc relative to Control).
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(Figure 5A; Supplementary Figure 4e). Consistent with these
results, U0126 treatment of control 1833 or RKIP-expressing
cells suppresses Myc binding to the LIN28 promoter
(Figure 4F). RKIP potentiates U0126-induced repression of
Myc binding to the LIN28 promoter, suggesting that RKIP also
regulates an MAPK-independent signalling pathway. Finally,
suppression of MEK/ERK signalling by U0126 treatment of
1833 cells induces let-7a and inhibits HMGA2 and Snail after
12 h of treatment (Figure 5B). Conversely, constitutively
active MEK1-EE expression suppresses let-7a and induces
HMGA2 and Snail in 1833 S153E RKIP-expressing cells
(Figure 5C). Taken together, these results implicate MEK
and ERK1,2 as upstream regulators of Myc, LIN 28, and let-7.
If RKIP downregulates invasion by ERK inhibition, then
ERK activation should promote invasion and rescue the
RKIP inhibitory phenotype. Consistent with this prediction,
MEK1 depletion by shRNA in 1833 cells decreased invasion
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Figure 6a). By contrast, constitutively active MEK1-EE
enhanced invasion without altering cell proliferation
(Figure 5D; Supplementary Figure 6b). Finally, tamoxifen
activation of a stably expressed oestrogen receptor/Raf
kinase fusion protein (DRaf-1:ER) enhances invasion in
1833 S153E RKIP-expressing cells (Figure 5E). As Raf could
theoretically activate non-MEK targets, we confirmed the key
function of MAPK in this effect by pretreating the DRaf-1:ER
cells with the MEK inhibitor U0126 under conditions that do
not alter cell proliferation (Supplementary Figure 6c). MEK
inhibition blocks the Raf-mediated increase and potentiates
RKIP suppression of invasion, consistent with the
lack of complete MAPK inhibition by RKIP (Supplementary
Figure 6d).
These results support a model whereby RKIP negatively
modulates Raf-1/MEK/ERK1,2 activity, leading to the inhibi-
tion of Myc and LIN28 and the induction of let-7. Let-7
inhibits HMGA2, and suppression of HMGA2 blocks the
induction of Snail transcription and other genes involved in
tumour cell invasion and metastatic colonization (Figure 5F).
This scheme highlights the function of LIN28 as a key target
of RKIP suppression. If RKIP regulates let-7 by inhibiting
LIN28 expression in breast tumour cells, then co-transfection
of LIN28 should rescue the metastatic phenotype. To test this
prediction, we injected luciferase-labelled 1833 cells co-ex-
pressing either a control vector or wt RKIP in the presence or
absence of stably expressed LIN28 directly into the left
cardiac ventricle of mice. Bioluminescence imaging analysis
of 1833 cells expressing wt RKIP and LIN28 showed compar-
able colonization and growth of bone metastasis with that
observed for control 1833 cells (Figure 5G), confirming
that RKIP suppresses and LIN28 promotes breast cancer
metastasis.
Discussion
The results presented herein move from RKIP repression of
metastasis and invasion to successive functions for HMGA2
and Snail, let-7, LIN28, Myc, and finally the Raf/MEK/ERK
cascade in the RKIP regulatory mechanism (see Figure 5F).
These data represent the first direct evidence that let-7
regulates not just tumour growth but also key steps in
metastasis. We show that processing of at least some let-7
isoforms is dependent upon LIN28 expression, and that
LIN28 is required for bone metastasis by a highly aggressive
basal-subtype breast cancer. Finally, we show that MAPK
(ERK1,2) negatively regulates let-7 by inducing LIN28 expres-
sion through Myc transcription. RKIP regulates this cascade
through partial inhibition of both the amplitude and kinetics
(data not shown) of ERK activation. As let-7 inhibits Ras
(Johnson et al, 2005), an upstream activator of Raf-1, these
data implicate let-7 in a positive feedback loop. A study
showing negative regulation of RKIP transcription by Snail
highlights another potential feedback loop (Beach et al,
2007). RKIP also regulates Myc by an MEK/ERK-independent
pathway as illustrated in the ChIP assay, showing Myc
regulation of LIN28 transcription. Thus, although this
mechanism is depicted as a linear pathway, it is part of a
larger network involving feedback regulatory pathways, cross
talk, and other RKIP targets.
The MDA-MB-231 metastatic cell line used in this study is a
basal-like subtype of breast carcinoma that represents a
highly aggressive but small fraction of breast tumours. We
chose to focus on an enriched metastatic population derived
from this line because we were investigating whether RKIP
expression is sufficient to suppress metastatic cells as op-
posed to preventing progression to a metastatic phenotype.
Thus we have not addressed the question in this study of the
function of RKIP in tumour progression, particularly with
regard to other subtypes, such as invasive luminal breast
cancer. It is interesting to note that, in contrast to some other
breast cancer subtypes, the MDA-MB-231 cells readily exhibit
changes related to EMT (Waerner et al, 2006; Sarrio et al,
2008). Thus, it is most likely that the signalling cascades in
these different breast tumour populations and the function of
RKIP in their regulation are context specific.
Figure 5 RKIP regulates let-7 in part through the MAPK pathway, and LIN28 reverses the inhibition of bone metastasis by RKIP. (A) MEK1
regulates LIN28 and Myc in 1833 cells. Constitutively, active MEK induces LIN28 and Myc. The 1833 cells expressing S153E RKIP were
transfected with control vector (C) or MEK1-EE for 48 h. LIN28 was also assayed by qRT–PCR. MEK1, Myc, lIN28, and a-tubulin expression
were measured by western blot. Conversely, stable depletion of MEK by lentiviral shRNA downregulates LIN28 and Myc in 1833 cells. Results
represent the mean±s.d. for three samples (P¼ 0.005 for shMEK and P¼ 0.001 for MEK1-EE relative to Control). Immunoblot results are
representative of at least three independent experiments. (B) Inhibition of MEK by U0126 induces let-7a and inhibits HMGA2 and Snail. Blot:
1833 cells treated with or without the MEK inhibitor U0126 (10mM, 12 h) were lysed and immuoblotted with antibodies to HMGA2 or tubulin.
Graphs: 1833 cells were treated with 10mM U0126 for the indicated times, and let-7a was assayed by qRT–PCR. Snail expression was
quantitated by qRT–PCR. Results represent the mean±s.d. for three samples (Let-7: P¼ 0.001, 0.01, and 0.03 for 12, 18, and 24 h, respectively,
relative to Control; Snail: P¼ 0.01, 0.004, and 0.01 for 12, 18, and 24 h, respectively, relative to Control). Results are representative of at least
three independent experiments. (C) Constitutively active MEK inhibits let-7a expression and induces HMGA2 and Snail. The 1833 cells
expressing S153E RKIP were transfected with control vector or MEK1-EE for 48 h, and let-7a and Snail were assayed by qRT–PCR. Results
represent the mean±s.d. for three independent samples (Let-7a: Po0.02 for MEK1-EE relative to Control; Snail: P¼ 0.01 for MEK1-EE relative
to Control). MEK1 and HMGA2 expression were measured by western blot. Results are representative of at least three independent
experiments. (D) MEK regulates invasion. Left: 1833 cells expressing either vector control or shRNA for MEK1 were assayed for invasion
as described in Materials and methods. Results represent the mean±s.d. for three independent samples (P¼ 0.004 for shMEK1 relative to
Control). Right: 1833 cells expressing either vector control or an expression vector for MEK1-EE were assayed for invasion as described in
Materials and methods. Results represent the mean±s.d. for three independent samples (Po0.005 for MEK1-EE relative to Control).
(E) Inducible Raf kinase rescues the inhibition of invasion caused by S153E RKIP. The 1833 cells expressing S153E RKIP and transfected
with control vector or DRaf-1:ER were untreated or treated with tamoxifen (4-HT). Results represent the mean±s.e. for three independent
samples (Po0.001 for S153E RKIPþDRaf-1:ERþHT relative to S153E RKIP Control; Po0.001 for S153E RKIPþDRaf-1:ERþHT relative S153E
RKIPþDRaf-1:ER). (F) Scheme showing the mechanism for RKIP regulation of invasion and metastasis through the MAPK/LIN28/let-7
pathway. (G) LIN28 overcomes the inhibitory effect of wt RKIP on bone metastasis. The 1833 cells expressing luciferase and either control
vector or wt RKIP were stably transfected with control vector or LIN28 and injected into the left ventricle of the mice (Control, six mice; LIN28,
5 mice; wt RKIP, six mice; wt RKIPþLIN28, five mice), and mice were imaged for luciferase activity after 3 weeks. Results represent the
mean±s.d. for the animals (P¼ 0.001 for wt RKIP relative to Control, and P¼ 0.01 for wt RKIPþLIN28 relative to wt RKIP).
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Epithelial–mesenchymal transition is a complex process
involving loss of epithelial genes and acquisition of mesench-
ymal genes. We do not have any evidence that RKIP induces
expression of epithelial genes or is sufficient to reverse EMT.
For example, unlike miR-200 (Burk et al, 2008; Gregory et al,
2008; Korpal et al, 2008; Park et al, 2008), RKIP does not
regulate E-cadherin expression. However, we have observed
some inhibition of vimentin expression by the RKIP mutant
construct, and we consistently see a decrease in Snail expres-
sion, a factor that can contribute to the mesenchymal transi-
tion among other functions. Nonetheless, the relatively small
change in Snail expression suggests that Snail is not the
major mediator of HMGA2 action. We also see consistent
reduction in HMGA2, a gene that we have shown to enhance
invasion. HMAG2 regulates a number of target genes that
contribute to invasion and metastasis independent of Snail
(Yun et al., manuscript in preparation). Finally, we do not see
a strong morphological change in the cells indicative of
transition back to the epithelial phenotype. Therefore,
although RKIP may partially counteract EMT by inhibiting
some genes required for the mesenchymal phenotype, the
evidence is strongest for a function in suppressing invasion
and metastasis.
Our results add let-7 to the list of microRNAs that have
recently been implicated in breast tumour cell metastasis (Ma
et al, 2007; Tavazoie et al, 2008) and represent the first
signalling cascade mediated by a tumour metastasis suppres-
sor protein that regulates let-7. The data presented here are
supported by a recent report that let-7 inhibits tumorigenesis
in a breast cancer stem cell line (Yu et al, 2007a). As either
Myc (along with OCT3/4, SOX2, and KLF4) or LIN28 (along
with OCT4, SOX2, and NANOG) is sufficient to transform
human fibroblasts into pluripotent stem cells (Takahashi
et al, 2007; Yu et al, 2007b), our results raise the possibility
that RKIP negatively regulates tumour-initiating stem cells.
Finally, as a potent inducer of let-7, RKIP represents an
important therapeutic target and diagnostic marker.
Materials and methods
Cell culture and reagents
MDA-MB-231 cells were grown in a complete medium consisting
of RPMI-1640 supplemented with 10% fetal bovine serum (FBS),
50 U/ml penicillin and 50mg/ml streptomycin (Invitrogen Corp.,
Carlsbad, CA). The bone (1833) and lung (4175) metastatic breast
cancer cells were grown in a complete medium consisting of DMEM
supplemented with 10% FBS, 50 U/ml penicillin, and 50mg/ml
streptomycin. Cells were treated with EGF (Biomedical Technolo-
gies Inc., Stoughton, MA) for 5 min at 50 ng/ml or with U0126
(Fisher, Pittsburgh, PA), used at 10mM, for 24 h, or as labelled for
time-course experiments.
Antibodies specific for vimentin (sc-32322), E-cadherin (sc-
21791), a-catenin (sc-7894), N-cadherin (sc-7939), MEK1 (sc-219),
and a-tubulin (IgG2a,,sc-5286 and IgM, sc-8035) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies for
ppERK1/2 (9101) and pMKK1/2 (9121) were purchased from Cell
Signaling Technology (Danvers, MA), the antibody for c-Myc
(M5546) was purchased from Sigma-Aldrich (St Louis, MO), and
the antibody for HMGA2 (59170AP) was purchased from BioCheck
Inc. (Foster City, CA). Anti-RKIP antisera used was generated by
immunizing rabbits with purified GST-RKIP (a-RKIP). The DRaf-
1:ER expression vector was generously provided by M McMahon
(Samuels et al, 1993). siRNA for Myc (M00328204) and control
(D001206405) were purchased from Dharmacon (Lafayette, CO).
Pre-miR control (AM17111), pre-miR let-7a (AM17100), anti-miR
control (AM17010), and anti-miR let-7a (AM17000) were purchased
from Ambion (Austin, TX). LIN28 antibodies were purchased from
R&D Systems (Minneapolis, MN).
Generation of stable cell lines
Raf kinase inhibitory protein rescue cell lines were generated by
transducing target cells with HA–RKIP wt or HA–RKIP S153E sub-
cloned into a pCDH1-CMV-MCS1-EF1-copGFP lentiviral vector
(System Biosciences, Mountain view, CA). Stable RKIP depletion
in MCF10A cells was achieved using shRNA retroviral vectors as
described earlier (Trakul et al, 2005). Stable bone metastatic cells
(1833) expressing LIN28 were generated by transducing cells with a
pMSCV-puro-IRES-GFP retroviral vector. Cells were transfected
using LT-1 transfection reagent (Invitrogen Corp.), using the
manufacturer’s protocol; 24 h after transfection, cells were selected
and maintained in 0.5mg/ml puromycin. MEK1 knockdown
(shMEK1), LIN28 knockdown (shLIN28), and HMGA2 knockdown
(shHMGA2) were achieved by transducing the bone metastatic cells
(1833) with the respective shRNAs in a pLKO.1 lentiviral vector
(Open Biosystems, Huntsville, AL). Cell lines inducible for let-7g
expression were constructed by the sequential transductions of
lentivirus containing let-7g under the control of a Tet-response
element (TRE), and a retroviral vector (pREVTet-On, Clontech)
encoding rtTA which in the presence of doxycycline (Dox) binds to
TRE to activate transcription (Kumar et al, 2008). In addition, the
lentiviral vector encoded puromycin resistance and the retroviral
vector encoded neomycin resistance allowing for the selection of
stable cell lines at each step.
Immunoblotting
Cells were washed twice with cold phosphate-buffered saline (PBS)
on ice and then lysed in cold 1 SDS-sample buffer. The lysates
were immediately boiled at 1001C and then centrifuged at 14 000 g
for 10 min. Proteins were resolved on an SDS–PAGE gel before
immunoblotting and then detected using either enhanced chemo-
luminescence western reagents (GE healthcare, Piscataway, NJ) or
the membranes were scanned using the Odyssey Infrared Imaging
System (LI-COR Biosciences, Lincoln, NE). For analysis using the
Odyssey System, membranes were probed with an IR dye-tagged
secondary antibody (LI-COR Biosciences) rather than an HRP-
tagged secondary antibody.
Transient transfection
Cells were transiently transfected using LT-1 transfection reagent
(Invitrogen) using the manufacturers’ protocol or using the
Nucleofector Kit V (Amaxa Biosystems, Gaithersburg, MD) and
program X-013 for electroporation.
In vitro cell invasion assay
The invasive capability of the different breast cancer cell lines was
evaluated in a 24-well plate using 8-mm-pore-size polycarbonate
inserts (BD Biosciences, Bedford, MA). Briefly, the inserts were
coated with 50mg Matrigel basement membrane matrix (BD
Biosciences), which was reconstituted in serum-free medium. To
assess the ability of cells to invade, 2104 breast cancer cells were
seeded on top of the polymerized matrigel in serum-free medium,
whereas complete medium (10% FBS) was placed in the lower
compartment. The plates were then incubated for 24 h at 371C, at
the end of which the cells were washed with PBS and then the cells
on the lower part of the insert were fixed with 4% paraformalde-
hyde for 10 min. The cells were then stained with Giemsa (1:5) for
15 min, the excess stain was rinsed off with PBS, and cells on top of
the insert that had not invaded were scraped off. Invasion was
quantified by counting the number of cells in 5 fields at  100
magnification per filter.
Quantitative ChIP analysis
Chromatin immunoprecipitation was carried out as described
previously (Wu et al, 2005). The chromatin fragments were
immunoprecipitated with 2mg of antibodies against either Myc
(N-262, Santa Cruz Biotechnology) or Jun (Santa Cruz Biotechnol-
ogy). Preimmune serum was used as negative controls. The
precipitated chromatin was purified by phenol–chloroform extrac-
tion and ethanol precipitation. DNA aliquots (2 ml) were analysed
by quantitative real-time PCR with the indicated primer pairs. The
amounts of products were determined relative to a standard curve
generated from a titration of input chromatin. Forward and reverse
primers for real-time PCR (50–30) ChIP analysis were as follows:
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LIN28(Myc), GGG AGG GCC CAT TCA TTT C and GGG TCC CCA
AAG CAG ATA CA; WNT5A(Myc), GTC GGG AAG TGG TCA AGG TT
and AAG TGC CAG AGA CAG ATG CT; CyclinD1(Jun), GTC CCA
GGC AGA GGG GAC and CGG CAA TTT AAC CGG GAG A; b-globin
promoter as a negative control, AGT GCC AGA AGA GCC AAG GA
and CAG GGT GAG GTC TAA GTG ATG ACA; and rRNA as an
internal control, ATT AGT CAG CGG AGG AAA AGA AAC and TCG
CCG TTA CTG AGG GAA TC.
Animal studies
All animal work was done in accordance with a protocol approved
by the Institutional Animal Care and Use Committee. BALB/c
female nude mice (Charles River) 6–7 weeks old were used for
animal studies. For intravasation assays, cells were orthotopically
injected (2106 cells/0.1 ml) into the second mammary fat pad of
anaesthetized mice (100 mg ketamine, per kg 10 mg xylazine per
kg). The mouse blood was taken from heart and lysed by the
addition of RBC lysis buffer (0.155 M NH4Cl, 0.01 M KHCO3, and
0.1 mM EDTA, pH 7.4) at a volume ratio of 3:1 lysis buffer:blood.
The samples were incubated for 10 min at 41C. Cells were collected
by centrifugation and resuspended in 1 ml of TRIzol reagent
(Invitrogen Corp.). The isolated RNA was analysed for human
and mouse GAPDH by qRT–PCR.
For bone metastasis assays, 105 cells in PBS (0.1 ml) were
injected into the left ventricle of mice. Mice were imaged for
luciferase activity using an IVIS200 Imaging System (Xenogen). Ten
minutes before in vivo imaging, mice were anaesthetized with 2%
isoflurane and injected intraperitoneally with D-luciferin (100 mg/kg
in PBS).
RNA isolation and reverse transcription
mRNA was isolated using TRIzol reagent (Invitrogen Corp.), using
the manufacturer’s protocol. Briefly, cells were lyzed in TRIzol,
followed by a phenol/chloroform (Invitrogen Corp.) extraction to
remove impurities. RNA in the aqueous phase was then precipitated
using isopropanol, washed with ethanol, and dissolved in DNase–
RNase-free water (Invitrogen Corp.). The isolated RNA was then
treated with DNase (Turbo DNA-free, Applied Biosystems, Foster
City, CA), following the manufacturer’s protocol, before being
purified using the RNeasy Mini Kit (Qiagen, Valencia, CA). A
quantity of 2mg RNA was then reverse-transcribed using the high-
capacity cDNA Reverse Transcription Kit from Applied Biosystems.
For microRNA isolation, we used the mirVana microRNA
isolation kit (Applied Biosystems) and followed the manufacturer’s
protocol. Reverse transcription of 10 ng of isolated microRNA was
carried out using the high-capacity cDNA reverse transcription kit
(Applied Biosystems), and a specific microRNA primer provided
with the TaqMan MicroRNA Assay (Applied Biosystems) was used.
RT–PCR
Quantification of RNA and microRNA was performed by real-time
RT–PCR using the Applied Biosystems 7500 Fast Real-Time PCR
System. For mRNA, a TaqMan Gene Expression Assay (Applied
Biosystems) for the gene of interest was used in conjunction with
ABsolute QPCR Low ROX Mix (Thermo Fisher Scientific, Pittsburgh,
PA). For microRNA, a TaqMan MicroRNA Assay (Applied Biosys-
tems) was used along with TaqMan Universal PCR Master Mix,
No AmpErase UNG (Applied Biosystems). Relative quantification
was through the 2DDCt method. For let-7 analysis, the Primary
microRNA primer sequences were as follows (Jiang et al, 2005):
Let-7a-1 forward: CCT GGA TGT TCT CTT CAC TG
Let-7a-1 reverse: GCC TGG ATG CAG ACT TTT CT
Let-7g forward: AGC GCT CCG TTT CCT TTT
Let-7g reverse: CCC CAC TTG GCA GCT G
Cell proliferation assays
Cell proliferation assays were performed using CellTiter-Blues
assay (Promega, Madion, WI) as described by the manufacturer.
Briefly, 2000 cells were seeded in a 96 well plate. After 24 h, 20 ml of
CellTiter-Blue reagent was added to each well and incubated for 2 h.
Fluorescence measurements were used to record data with 560 nm
for excitation and 590 nm for fluorescence emission.
Tetracycline induction of let-7g
Cells were treated with 2 mg/ml doxycycline for in vitro studies. For
animal studies, 1833 let-7g tet-inducible cells were plated in the
presence of 2mg/ml doxycycline. Twenty-four hours later, cells (105)
were injected into the left ventricle of mice. Two days later, mice
were administered drinking water containing 4% sucrose only or
2 mg/ml doxycycline and 4% sucrose. Mice were imaged for
luciferase activity after 3 weeks.
Statistical analysis
Samples were analysed by the two-sample Student’s t test assuming
unequal variances (two-tailed). Excel software was used for
statistical analysis. P-values were calculated for samples from three
independent experiments unless otherwise indicated.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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